Background Sars-Cov-2 is a novel corona virus associated with significant morbidity and mortality. Remdesivir and Dexamethasone are two treatments that have shown to be effective against the Sars-Cov-2 associated disease. However, a cost-effectiveness analysis of the two treatments is still lacking. Objective The cost-utility of Remdesivir, Dexamethasone and a simultaneous use of the two drugs with respect to standard of care for treatment Covid-19 hospitalized patients is evaluated, together with the effect of Remdesivir compared to the base model but based on alernative assumptions. Methods A decision tree for an hypothetical cohort of Covid-19 hospitalized patients, from an health care perspective and a one year horizon is specified. Efficacy data are retrieved from a literature review of clinical trials, whilst costs and utility are obtained from other published studies. Results Remdesivir, if health care costs are related to the days of hospitalization, is a cost saving strategy. Dexamethasone is cost effective with an ICER of
【저자키워드】 COVID-19, Dexamethasone, SARS-CoV-2, Remdesivir, Cost effectiveness, Decision tree, Cost Utility, pharmacoeconomics, 【초록키워드】 Treatment, Mortality, Hospitalization, clinical trials, drug, hospitalized patients, Cohort, Health, sensitivity analysis, morbidity and mortality, utility, disease, Care, novel corona virus, Analysis, Standard of care, literature review, standard care, Perspective, positive, thresholds, parameter, objective, effective, patient hospitalization, Result, shown, tested, evaluated, hospitalized patient, hypothetical, retrieved, 【제목키워드】 Treatment, utility, Analysis, hypothetical, hospitalised COVID-19 patient,